Bioactive glasses in bone regeneration: a comprehensive review of in vivo studies and translational challenges
Year: 2026
Type: article
Abstract: This review evaluates the in vivo performance of bioactive glasses (BGs) as grafts for large bone defects. A systematic search of PubMed/Medline and Web of Science, with citation searching, identified 31 in vivo studies published to 30 November 2025, enrolling 694 animals (mean follow-up 11.4 weeks). Grouping the evidence by glass family yields three findings. First, the commercial compositions remain the benchmark: 45S5 particulate bridges ∼80% of the interparticle space with bone by 6–12 weeks in the rabbit femoral condyle, outperforming size-matched hydroxyapatite, while S53P4 osteostimulates reliably but degrades slowly. Second, degradation rate rather than bioactivity most often limits performance, and its effect is non-monotonic: B2O3 substitution in 13-93 accelerates apatite conversion yet suppressed regeneration in fibrous scaffolds, and sol-gel 70S30C foams gave 39% bone ingrowth only when preconditioned to limit calcium release, against 10% when dry. Third, architecture is as decisive as chemistry: with pore interconnect size matched, ICIE16 foams gave the fastest early ingrowth (31.1% at 4 weeks) but 3D-printed scaffolds of the same glass the highest at 10 weeks (36.3%). Because 45S5 and S53P4 are long-established clinical products, the bottleneck is not bioactivity but delivering amorphous, load-sharing porous scaffolds whose degradation matches host remodelling, tested in large-animal, load-bearing models.
Source: European Journal of Materials
Language: English
Subfield: Biomedical Engineering
Field: Engineering
Domain: Physical Sciences
Open Access status: gold
Estimated APC paid: $1,590
OpenAlex ID: W7237357201
